Clinical activity was seen across all PD-L1 groups defined by PD-L1 intensity score, tumor-membrane staining score, and histiocyte score (QualTek IHC assay); 90.4% of patients had an intensity score of 3; 88.1% had 100% PD-L1+ membrane staining; 71.8% had a histiocyte score of 3. Here, CD274 is linked to neoplasm.